Program
Cetirizine
Also written as “Cetirizine (Zyrtec)”, “AC-170 0.24%” and “Ceterizine”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Hypersensitivity · Urticaria · Conjunctivitis, Allergic · Rhinitis, Allergic, led by 12 companies.
Drug pageCetirizine: every studyMany companies study it; this page follows only the 31 they lead. All 67 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aciex Therapeuticsits history only | 70 open or running | phase 3since Apr 7, 2011 | Apr 7, 2011 | none ahead |
| GlaxoSmithKlineits history only | 50 open or running | phase 4since Aug 1, 2013 | Jun 19, 2007 | none ahead |
| JDP Therapeuticsits history only | 30 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Johnson & Johnson | 30 open or running | phase 4since Sep 30, 2016 | Mar 23, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 17, 2008 | Oct 17, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Feb 6, 2025 | Feb 6, 2025 | none ahead |
| Nicox Ophthalmicsits history only | 10 open or running | phase 3since Apr 20, 2016 | Apr 20, 2016 | none ahead |
| TerSera Therapeuticsits history only | 10 open or running | phase 2since Dec 3, 2019 | Dec 3, 2019 | none ahead |
Also a collaborator on its studies: Algorithme Pharma, ORA, Pfizer and Ohm Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 23, 2011First study: phase 1 study in HypersensitivityFirst studyNCT01322282 · 36 enrolled · Canada
- Sep 30, 2016Phase 4 study in Rhinitis, AllergicNCT02932774 · 683 enrolled
- Dec 10, 2018Phase 1 study in HypersensitivityNCT03772158 · 40 enrolled · Canada
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03772158Hypersensitivity · Canada | 1 | Completed | Feb 3, 2019 | 40 |
| NCT02932774Rhinitis, Allergic | 4 | Completed | Jul 2001 | 683 |
| NCT01322282Hypersensitivity · Canada | 1 | Completed | Mar 2011 | 36 |
How it is read
Names in the registry
- “Cetirizine”, 6 entries
- “Cetirizine (Zyrtec)”, 5 entries
- “AC-170 0.24%”, 5 entries
- “Ceterizine”, 2 entries
- “cetirizine”, 2 entries
Codes read as this program: JDP205.
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 8 studies
- Hypersensitivity, 6 studies
- Urticaria, 5 studies
- Conjunctivitis, Allergic, 5 studies
- Rhinitis, Allergic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.